Relapsed or refractory multiple myeloma research hub
12 indexed studies · 6 currently recruiting
- completedPhase III
A study comparing talquetamab in combination with daratumumab or in combination with daratumumab and pomalidomide versus daratumumab in combination with pomalidomide and dexamethasone in participants with multiple myeloma that returns after treatment or is resistant to treatment
This study tests whether a new medicine called talquetamab, given alongside other cancer drugs, helps people with multiple myeloma that has returned or stopped responding to past treatments. Researchers want to see if these new combinations keep the cancer under control for longer than the current standard treatment.
United Kingdom · England · Belgium - recruitingPHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous treatments. It looks at a new drug, mezigdomide, combined with standard medicines (bortezomib and dexamethasone), against another combination (pomalidomide, bortezomib, and dexamethasone). The aim is to see which combination is more effective and safe.
United States · Argentina · Australia - active not recruitingPHASE3
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
This study is looking into a new combination of medicines for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination with a standard one to see if the new option works better.
United States · Argentina · Australia - active not recruitingPHASE3
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new treatment, teclistamab, with existing therapies for multiple myeloma that has come back or not responded to previous treatments. It aims to see how well teclistamab works and if it's safe for people with this condition.
United States · Australia · Austria - recruitingHuman Pharmacology (Phase I)- Other
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
This early-stage study is looking at a new medicine called belantamab mafodotin for people with multiple myeloma. It specifically checks how the medicine works in patients whose liver is healthy compared to those with liver problems. This helps make sure future studies are safe and effective.
Greece - recruitingHuman Pharmacology (Phase I)- Other
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine called Forimtamig for people in the UK with multiple myeloma that has come back or isn't responding to treatment. We want to see if different doses are safe and how the medicine works in the body.
Spain · Italy · Denmark - recruitingPhase III
A study comparing JNJ-79635322 and an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody in participants with relapsed or refractory multiple myeloma (Trilogy-4)
This study looks at a new injection called JNJ-79635322 for multiple myeloma that has come back or isn't responding to treatment. We're comparing it to another approved drug, teclistamab, to see if it helps patients aged 18 and over who have tried other therapies.
United Kingdom · England · Scotland - active not recruitingPHASE1
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine, JNJ-87562761, for multiple myeloma that has come back or not responded to past treatments. Its main goals are to find a safe and effective dose and understand any side effects.
Canada · South Korea · Spain - authorisedTherapeutic confirmatory (Phase III)
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)
This study is testing a new cell therapy (AZD0120) for people with multiple myeloma that has come back or isn't responding to treatment. It compares this new therapy with standard treatments to see which works best.
Norway · Poland · Spain - recruitingPHASE1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
This study is testing a new drug, JNJ-79635322, for people with multiple myeloma or AL amyloidosis that hasn't responded well to previous treatments. It aims to find the safest and most effective dose, and to understand its safety and how well it's tolerated.
United States · Belgium · France - authorisedTherapeutic exploratory (Phase II)
A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)
This study looks at new ways to use an existing medicine, belantamab mafodotin, along with standard treatments for multiple myeloma that has come back or not responded to past treatments. It aims to see how well these combinations work and if they are safe.
France · Germany · Greece - not yet recruitingPHASE3
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination (Etentamig plus Pomalidomide) with standard treatments to see if it's safe and helps improve the disease.
United States · Australia · Canada